Search Bar & Filters
Found 25 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
This research aims to evaluate how human lactoferrin combined with low-dose iron affects iron levels, aerobic fitness, and lactate metabolism in women who exercise and have low iron stores. The study focuses on healthy menstruating women aged 18 to 45 years with serum ferritin below 35 gL, aiming to understand if lactoferrin can improve iron regulation and exercise outcomes. Iron deficiency is common in active women and can reduce oxygen delivery and exercise performance, making this study important for finding better supplementation methods. Participants will be randomly assigned to one of three groups for an 8-week period receiving 100 mg lactoferrin plus 5 mg iron daily, 300 mg lactoferrin plus 5 mg iron daily, or a placebo plus 5 mg iron daily. The study uses a triple-blind design where neither participants nor researchers know who receives which treatment. The intervention is oral supplementation taken daily, and participants will attend six visits including screening, baseline, and follow-ups at weeks 2, 4, 6, and 8. During the study, participants will undergo blood tests to measure iron biomarkers and blood parameters, along with assessments of aerobic capacity using treadmill tests measuring VO2peak, time to exhaustion, and blood lactate levels. Questionnaires will evaluate gastrointestinal symptoms, menstrual symptoms, quality of life, and recovery perception. Daily supplement adherence and any side effects will be monitored throughout. The primary outcome is the change in serum ferritin concentration over time, while secondary measures include changes in hemoglobin, hematocrit, red blood cell count, and exercise performance indicators.
Actively Recruiting
Bipolar disorder is a serious and chronic mood condition affecting both adults and pediatric populations in the United States. This research aims to evaluate the safety and effectiveness of Icalcaprant in treating adults diagnosed with bipolar I or II disorder, focusing on depressive episodes. The study is a phase 2, randomized, placebo-controlled trial enrolling about 195 adults across approximately 35 sites. Participants will be randomly assigned to one of three groups two different doses of oral Icalcaprant or a matching placebo. They will take the assigned oral capsules once daily for six weeks. After the treatment period, there will be a four-week safety follow-up to monitor participants health. During the study, participants will attend regular visits at hospitals or clinics for medical assessments, blood tests, side effect monitoring, and questionnaires. The main outcomes measured include changes in depression severity using the Montgomery-sberg Depression Rating Scale and monitoring adverse events throughout the treatment and follow-up periods. This study is sponsored by AbbVie and aims to better understand treatment options for bipolar depression.
Actively Recruiting
Researchers are evaluating the effectiveness of AXS-05 compared to bupropion in preventing the return of depressive symptoms in adults with major depressive disorder MDD who have already responded to treatment with AXS-05. This is a randomized, double-blind, active-controlled study conducted across multiple centers, aiming to assess relapse prevention in people diagnosed with MDD without psychotic features. Participants will first receive open-label AXS-05 treatment for up to 10 weeks, during which their response and remission will be monitored. Those who meet response and remission criteria will then be randomly assigned to continue taking AXS-05 or switch to bupropion tablets, both taken twice daily, for a double-blind treatment period lasting up to 26 weeks or until depressive symptoms relapse. Throughout the study, participants will be closely monitored for signs of depressive symptom relapse using regular assessments. The main outcome measured is the time from randomization to relapse over the 26-week double-blind period. The entire study period includes an initial 10-week treatment phase followed by up to 26 weeks of randomized treatment, with ongoing evaluation by the study team to track safety and treatment effects.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of Xanomeline and Trospium Chloride in children and adolescents with psychiatric disorders, including schizophrenia and autism-related irritability. This Phase 3, open-label study is sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company, aiming to understand how these drugs affect young patients over an extended period. Participants will receive specified doses of KarXT or the combination of KarXT and KarX-EC depending on their condition. The study is non-randomized and open-label, meaning all participants receive the study treatment without placebo comparison. The treatment period can last up to 56 weeks, during which the safety and side effects of the medications will be closely monitored. Throughout the study, participants will undergo regular assessments to monitor treatment emergent adverse events, serious adverse events, and special interest adverse events. Additional evaluations include symptom assessments using scales like the Columbia Suicide Severity Rating Scale, Simpson-Angus Scale, Abnormal Involuntary Movement Scale, and Barnes-Akathisia Rating Scale. The study involves continuous safety monitoring and lasts up to 56 weeks, with follow-up to evaluate both tolerability and any psychiatric symptoms.
Actively Recruiting
Researchers are evaluating the effectiveness of centanafadine extended-release capsules taken once daily in adults who have attention-deficithyperactivity disorder ADHD along with emotional dysregulation ED. This Phase 3b, open-label study aims to understand how this treatment may affect symptoms of ADHD and emotional regulation in this population. The trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. and includes adults aged 18 to 65 years. Participants in this study will receive centanafadine XR capsules at a dose of 328.8 milligrams orally once daily for eight weeks. This single-group trial does not include a placebo or comparator group. The treatment period lasts for eight weeks, during which participants take the study drug daily to assess its effects on ADHD and emotional dysregulation symptoms. During the study, participants will be monitored through various assessments including the Wender-Reimherr Adult Attention Deficit Disorder Scale WRAADDS, Clinical Global Impressions for ADHD severity, executive function evaluations, and emotional regulation scales. Safety is also monitored by tracking adverse events and suicidal ideation or behavior. The main outcome measure assesses changes in ADHD symptoms over the eight-week treatment period, with study participation lasting approximately two months.
Actively Recruiting
Researchers are evaluating ACP-211, a medication, to treat adults with major depressive disorder MDD who have not improved with current antidepressant therapy, including those with treatment-resistant depression. This phase 2 trial aims to determine if ACP-211 reduces depression symptoms better than a placebo and to monitor any side effects experienced by participants. Participants are randomly assigned to receive either 600 mg or 300 mg of ACP-211, or a matching placebo, all taken orally twice a week. The study is double-blind, meaning neither participants nor researchers know who receives which treatment, to fairly assess the effects. The main treatment period lasts 28 days with doses given twice weekly. During the study, participants are assessed for changes in depression severity using the Montgomery-sberg Depression Rating Scale MADRS at baseline, day 2, and day 28, among other measures. Additional evaluations include clinical global impression scores and remission rates. Safety and side effects are closely monitored throughout. The total participation time spans from screening to the end of treatment and follow-up, concluding around 28 days after treatment begins.
Actively Recruiting
Evaluation of TSND-201 Capsules Versus Placebo for Treating Post Traumatic Stress Disorder in Adults
Researchers are evaluating the safety and effectiveness of TSND-201 in adults diagnosed with Post Traumatic Stress Disorder PTSD. This Phase 3 trial is designed to test how well TSND-201 works compared to a placebo in treating PTSD symptoms. Eligible participants must have a current diagnosis of PTSD lasting at least six months and have tried previous treatments such as medication or trauma-focused psychotherapy. Participants will be randomly assigned to one of three groups two different doses of TSND-201 or a placebo. Each participant will take capsules orally once a week for four consecutive weeks during the Treatment Period. After completing treatment, participants will enter an 8-week Follow-up Period to monitor their progress without additional treatment. Throughout the study, participants will be assessed using the Clinician-Administered PTSD Scale for DSM-5 CAPS-5 to measure changes in PTSD symptom severity from baseline up to 12 weeks. Regular interviews and questionnaires will be completed to track safety and efficacy. The study aims to complete by December 2027, with careful monitoring to ensure participant well-being throughout the trial.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the effects of daily geranylgeraniol GG supplementation on muscle strength, body composition, and aerobic fitness in healthy, physically active adults aged 30 to 60 years. This randomized, double-blind, placebo-controlled trial aims to understand how different doses of GG influence muscle health and related physiological markers over an 8-week period. Participants will be randomly assigned to one of three groups receiving daily doses of either a placebo olive oil, 150 mg GG, or 300 mg GG. Supplements are taken with water at a consistent time each day for 8 weeks. The study includes a screening visit and testing at baseline, week 4, and week 8 to track changes over time. During the study, participants undergo strength testing bench press and leg press, muscular endurance assessments, aerobic capacity measurement via treadmill, and body composition analysis using advanced techniques. Blood samples will be collected to monitor metabolism-related biomarkers and safety. Participants also complete mood and quality of life questionnaires, provide dietary logs, and give fecal samples. Safety is tracked throughout, and the main outcomes focus on changes in strength and fat-free mass from start to week 8.
Actively Recruiting
Healthy Volunteer
Researchers are examining how different doses of glucosyl-hesperidin CITRAPEAK affect exercise performance, recovery, blood flow, cognitive function, mood, sleep, and fuel use in healthy, recreationally active adults aged 18 to 50. This randomized, double-blind, placebo-controlled study aims to understand dose-dependent effects in this population to support cardiovascular and cognitive health improvements. Participants will be randomly assigned to one of three groups a placebo group receiving a daily 400 mg cellulose supplement a group receiving 200 mg glucosyl-hesperidin plus 200 mg cellulose daily or a group receiving 400 mg glucosyl-hesperidin daily. The study lasts 8 weeks, with daily supplement intake monitored through logs. The design includes multiple visits with various assessments, including exercise testing, blood flow measurements, and cognitive evaluations. During the study, participants will undergo tests such as peak VO2 and Wingate anaerobic power assessments, blood flow analysis at multiple times post-supplement intake, and mood and sleep quality questionnaires. Researchers will track adherence via supplementation logs and measure changes in physical and cognitive performance, mood, sleep, and nitric oxide levels. Participation spans the full 8-week supplementation period with evaluations at baseline and week 8.
Actively Recruiting
Researchers are evaluating the efficacy and safety of SPN-821, a novel oral drug, as an additional treatment for adults with major depressive disorder MDD. This phase 2, multicenter, randomized, double-blind, placebo-controlled study focuses on adults diagnosed with MDD who continue to experience symptoms despite stable antidepressant therapy. The study aims to assess improvements in depression severity using standardized rating scales. Participants are randomly assigned to receive either SPN-821 at a dose of 2400 mg three 800 mg tablets or matching placebo tablets, both administered twice a week alongside their current antidepressant medication. The study includes a 2-week screening period to confirm eligibility, followed by a 4-week treatment period where participants receive the assigned study tablets. After completing treatment, participants undergo a safety follow-up phone call one week later to monitor any ongoing effects. During the study, participants will have their depression symptoms evaluated using the Montgomery-sberg Depression Rating Scale MADRS and Clinical Global Impression-Severity CGI-S scale at baseline and Day 29. Safety assessments and monitoring occur throughout the trial and during the follow-up call. Overall, the study participation lasts approximately 7 weeks including screening, treatment, and follow-up to understand the impact of SPN-821 on depressive symptoms and safety in adults with MDD.
1-10 of 25
1